Home » Stocks » Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. (MIRM)

Stock Price: $20.15 USD 0.27 (1.36%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 511.61M
Revenue (ttm) n/a
Net Income (ttm) -67.91M
Shares Out 25.39M
EPS (ttm) -9.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $20.15
Previous Close $19.88
Change ($) 0.27
Change (%) 1.36%
Day's Open 20.28
Day's Range 20.03 - 21.29
Day's Volume 47,342
52-Week Range 6.51 - 28.31

More Stats

Market Cap 511.61M
Enterprise Value 355.69M
Earnings Date (est) Aug 26, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.39M
Float 6.86M
EPS (basic) -7.12
EPS (diluted) -9.33
FCF / Share -2.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 543,958
Short Ratio 4.05
Short % of Float 4.59%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.41
Revenue n/a
Operating Income -70.59M
Net Income -67.91M
Free Cash Flow -55.62M
Net Cash 155.92M
Net Cash / Share 6.14
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -34.44%
ROE -60.80%
ROIC -69.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 4
Overweight 2
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(74.54% upside)
Current: 20.15
Target: 35.17
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-54.74
Net Income-52.55
Shares Outstanding11.49
Earnings Per Share-4.58
Operating Cash Flow-39.36
Capital Expenditures-0.28
Free Cash Flow-39.64
Cash & Equivalents117
Total Debt3.65
Net Cash / Debt113
Book Value130
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mirum Pharmaceuticals, Inc.
Country United States
Employees 41
CEO Christopher Peetz

Stock Information

Ticker Symbol MIRM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MIRM


Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.